Kiniksa Pharmaceuticals (KNSA) Price & Analysis

Compare

543 Followers

KNSA Stock Chart & Stats

$43.19

$0.18(0.88%)

At close: Jan 08 4:00 PM EST

$43.19

$0.18(0.88%)

Day’s Range― - ―

52-Week Range$17.82 - $43.73

Previous CloseN/A

Volume84.12K

Average Volume (3M)356.34K

Market Cap

$3.27B

Enterprise Value$2.77B

Total Cash (Recent Filing)$352.10M

Total Debt (Recent Filing)$9.72M

Price to Earnings (P/E)96.3

Beta0.56

Next Earnings

Mar 03, 2026

EPS Estimate

0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.23

Shares Outstanding45,161,020

10 Day Avg. Volume457,434

30 Day Avg. Volume356,336

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)3.22

Price to Sales (P/S)3.34

P/FCF Ratio55.59

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue4.62

Enterprise Value/Gross Profit8.76

Enterprise Value/Ebitda61.32

Forecast

1Y Price Target

$52.83

Price Target Upside22.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)1.05

Revenue Forecast (FY)$674.82M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceArcalyst generated $1B+ of sales driven by 16 consecutive quarters of growth with no signs of slowing.

Market ExpansionThere is significant room to continue to expand Arcalyst's opportunity, as the number of prescribers that have written Arcalyst still represents only a fraction of the potential prescribers.

Product InnovationArcalyst's launch continues to ramp and KPL-387 could offer more favorable dosing supporting a switch to significantly improve the company's bottom line.

Bears Say

Kiniksa Pharmaceuticals News

Kiniksa Advances KPL-387 Study for Recurrent Pericarditis: What Investors Should Know

Kiniksa Pharmaceuticals Ltd. Class A ($KNSA) announced an update on their ongoing clinical study. Kiniksa Pharmaceuticals recently announced...

4d ago

KNSA

Kiniksa price target raised to $55 from $45 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Kiniksa (KNSA) to $55 from $45 and keeps a Buy...

2M ago

KNSA

Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth

Kiniksa Pharmaceuticals Ltd. Class A ( ($KNSA) ) has released its Q3 earnings. Here is a breakdown of...

2M ago

KNSA

Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism

Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q3 earnings call. Read on for the main highlights...

2M ago

KNSA

Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating

Nicholas Lorusso, an analyst from TD Cowen, maintained the Buy rating on Kiniksa Pharmaceuticals. The associated price target...

2M ago

KNSA

Kiniksa riases FY25 ARCALYST net product revenue view $670M-$675M

Previous view $625M-$640M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...

2M ago

KNSA

Kiniksa expects current operating plan to remain cash flow positive

Kiniksa (KNSA) expects its current operating plan to remain cash flow positive on an annual basis. Published first...

2M ago

KNSA

Kiniksa reports Q3 EPS 23c, consensus 37c

Reports Q3 revenue $180.9M, consensus $167.36M. “Year to date, ARCALYST revenue has continued to grow, with the expanding...

2M ago

KNSA

Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis

Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) announced an update on their ongoing clinical study. Study Overview: Kiniksa Pharmaceuticals...

2M ago

KNSA

KNSA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) is scheduled to report 3rd quarter earnings on 10/28/2025, before the market...

2M ago

KNSA

Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals

Analyst Nicholas Lorusso of TD Cowen maintained a Buy rating on Kiniksa Pharmaceuticals, retaining the price target of...

2M ago

KNSA

Kiniksa announces Orphan Drug Designation for KPL-387

Kiniksa (KNSA) Pharmaceuticals announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to KPL-387 for...

2M ago

KNSA

Kiniksa price target raised to $50 from $45 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on Kiniksa (KNSA) to $50 from $45 and keeps...

2M ago

KNSA

Kiniksa granted orphan designation for treatment of pericarditis

Kiniksa (KNSA) Pharmaceuticals was granted FDA orphan designation for its treatment of pericarditis , according to a post...

2M ago

KNSA

KNSA FAQ

What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?

Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $17.82 and its highest was $43.73 in the past 12 months.

What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?

Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $3.27B.

When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?

Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is Mar 03, 2026 which is in 72 days.

How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?

Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Oct 28, 2025. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.324 by -$0.094.

Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?

According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?

Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.

What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?

Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.37.

How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?

Kiniksa Pharmaceuticals Ltd. Class A has 45,161,020 shares outstanding.

What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?

Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of $0.23 in its last earnings report, missing expectations of $0.324. Following the earnings report the stock price went down -2.882%.

Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?

Currently, no hedge funds are holding shares in KNSA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kiniksa Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

7.39%

Trailing 12-Months

Asset Growth

28.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kiniksa Pharmaceuticals Ltd. Class A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals (KNSA) Earnings & Revenues

Historic Earnings Reports

KNSA Company Deck

KNSA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong positive outlook for Kiniksa Pharmaceuticals with significant revenue growth, increased sales guidance, and a robust financial position. The company highlights the increased adoption of ARCALYST and its FDA Orphan Drug Designation for KPL-387. However, challenges remain with limited market penetration and increased operating expenses.View all KNSA earnings summaries

KNSA Stock 12 Month Forecast

Average Price Target

$52.83

▲(22.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","61":"$61","28.75":"$28.8","39.5":"$39.5","50.25":"$50.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,28.75,39.5,50.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.93,42.39692307692307,43.863846153846154,45.33076923076923,46.79769230769231,48.26461538461538,49.73153846153846,51.19846153846154,52.66538461538462,54.13230769230769,55.59923076923077,57.066153846153846,58.53307692307692,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.93,41.84538461538462,42.76076923076923,43.676153846153845,44.59153846153846,45.50692307692307,46.42230769230769,47.33769230769231,48.25307692307692,49.168461538461536,50.08384615384615,50.99923076923076,51.91461538461538,{"y":52.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.93,41.16615384615385,41.402307692307694,41.63846153846154,41.87461538461538,42.11076923076923,42.346923076923076,42.58307692307692,42.81923076923077,43.05538461538462,43.291538461538465,43.527692307692305,43.76384615384615,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.78,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >